|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.10.25 - 13:12
|
Newron: Zwischen zwei Polen (GoingPublic)
|
|
|
Bildnachweis: © Ashi – stock.adobe.com. Mit zwei großen Phase-III-Studien steht Newron an einem entscheidenden Punkt. Gelingt der Nachweis für Evenamide als Zusatztherapie bei Patienten mit behandlungsresistenter Schizophrenie („treatment-resistant schizophrenia“, TRS), […]
Der Beitrag Newron: Zwischen zwei Polen erschien zuerst auf GoingPublic.de....
|
|
|
|
|
|
|
|
|
|
|
16.09.25 - 13:06
|
Newron presents H1 2025 results and provides business update (Business Wire)
|
|
|
Ad hoc announcement pursuant to Art. 53 LRMILAN--(BUSINESS WIRE)--$NWRN #schizophrenia--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the half-year ended June 30, 2025, and provided a business update for 2025 and beyond.
Highlights H1 2025:
Evenamide
Clinical trials:
In May, the Company announced regulatory approval for its pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS). The program consists of two pivotal studies:
ENIGMA-TRS 1, an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients. Following a successful screening period, patient enrolment began post-period, in August 2025, with 12-week study results expected in Q4 2026
ENIGMA-TRS 2, approved ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
